1.1Single domain receptor binding
The recombinant domain folds independently and presents three exposed loops on an immunoglobulin framework. The loops form a composite surface that contacts the extracellular domain of human GIPR.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The recombinant domain folds independently and presents three exposed loops on an immunoglobulin framework. The loops form a composite surface that contacts the extracellular domain of human GIPR.
The fibronectin domain uses a beta sandwich to position three surface loops. Residues on those loops make hydrogen bonds and hydrophobic contacts with the extracellular domain of human GIPR.
Tandem ankyrin repeats form a rigid surface with contact residues distributed across adjacent repeats. Terminal capping repeats shield the hydrophobic core and stabilize the fold.
Hydrophobic residues pack inside the bundle and hold the helices in position. Side chains on the outward faces of two helices form a binding surface against the extracellular domain of human GIPR.
Base pairing forms stems that position exposed bases and ribose groups in a three-dimensional binding surface. Selection on cells expressing human GIPR enriches receptor binders, and counterselection on matched cells without GIPR depletes binders to other cell surface components.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A GIPR-binding antibody with the listed binding-loop sequences serves as the primary reagent for fluorescence imaging of frozen human tissue sections. A fluorophore-labeled secondary antibody binds the primary antibody after a wash. Matched sections processed with and without the primary antibody show the distribution of staining and the background contributed by the secondary reagent.
A 96-well plate holds GIPR-expressing cells and matched receptor-negative cells in parallel rows. Each cell type receives eight twofold dilutions of the GIPR-binding antibody, starting at 100 nM and ending at approximately 0.78 nM, with three wells per concentration. A fluorescent secondary antibody reports cell-associated primary antibody after washing. The concentration series produces a binding curve for each cell type.
A GIPR-binding antibody is coupled through its Fc region to protein G magnetic beads and used with a liquid chromatography tandem mass spectrometry system. The beads capture receptor from a detergent-solubilized membrane preparation that preserves the antibody-binding site. After washing, the captured material undergoes protease digestion, and the released peptides enter the chromatography system. GIPR-specific peptide signals are compared with signals from a matched capture using an isotype control.
A two-channel biolayer interferometry system carries GIPR-bearing nanodiscs on one sensor and a soluble beta-klotho extracellular domain on the other. Both sensors contact the same dilution series of the GIPR antibody–FGF21 fusion. Empty nanodiscs and unloaded sensors provide reference traces for the respective channels. The two sensorgrams report binding through the antibody and FGF21 portions of the fusion in separate measurements.
A fluorescently labeled GIPR-binding antibody marks surface receptor on cells during a cold incubation. After a wash, a heated imaging stage brings the cells to 37 °C, and a fluorescence microscope acquires images at fixed intervals. Image analysis software segments cell boundaries and intracellular puncta, then calculates the fraction of cell-associated fluorescence in intracellular puncta over time. Matched wells held cold provide a reference for surface-associated signal.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The amino acid sequence of CDR-L1 is ESVDSYDNSF (SEQ ID NO: 10).A · US 8,975,029 B2 · ¶ 37
In some embodiments, the antibody or antigen binding fragment thereof comprises: an immunoglobulin heavy chain CDR1 (CDR-H1) comprising the amino acid sequence set forth in SEQ ID NO: 1 (GYTFTSYG); an immunoglobulin heavy chain CDR2 (CDR-H2) comprising the amino acid sequence set forth in SEQ ID NO: 2 (ISAYNGNT); an immunoglobulin heavy chain CDR3 (CDR-H3) comprising the amino acid sequence set forth in SEQ ID NO: 9 (DMLVVPFDY); an immunoglobulin light chain CDR1 (CDR-L1) comB · US 2022/0010003 A1 · ¶ 4
The amino acid sequence of CDR-L2 is YVS (SEQ ID NO: 5).A · US 8,975,029 B2 · ¶ 31
The amino acid sequence of CDR-L3 is QHSNRWPLT (SEQ ID NO: 6).A · US 8,975,029 B2 · ¶ 31
The amino acid sequence of CDR-H1 is GYSFTSYW (SEQ ID NO: 1).A · US 8,975,029 B2 · ¶ 34
Described herein is a recombinant antibody or antigen binding fragment thereof that binds periostin, wherein the antibody or antigen binding fragment thereof comprises: an immunoglobulin heavy chain CDR1 (CDR-H1) comprising the amino acid sequence set forth in SEQ ID NO: 1 (GYTFTSYG); an immunoglobulin heavy chain CDR2 (CDR-H2) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2 (ISAYNGNT), 3 (ISAYSGNT), 4 (ISAYQGNT), 5 (ISAYTGNT), or 6 (ISAYDGNT); an immuB · US 2022/0010003 A1 · ¶ 4
The amino acid sequence of CDR-H2 is FYPGNSED (SEQ ID NO: 2).A · US 8,975,029 B2 · ¶ 34
The amino acid sequence of CDR-H3 is TRGTTLVAPGFDV (SEQ ID NO: 3).A · US 8,975,029 B2 · ¶ 34
In some embodiments, the antibody or antigen binding fragment thereof comprises: an immunoglobulin heavy chain CDR1 (CDR-H1) comprising the amino acid sequence set forth in SEQ ID NO: 1 (GYTFTSYG); an immunoglobulin heavy chain CDR2 (CDR-H2) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2 (ISAYNGNT), 3 (ISAYSGNT), 4 (ISAYQGNT), 5 (ISAYTGNT), or 6 (ISAYDGNT); an immunoglobulin heavy chain CDR3 (CDR-H3) comprising an amino acid sequence set forth in anyB · US 2022/0010003 A1 · ¶ 6
An empty cell means only that no passage was reproduced there.
There remains a need in the art for therapeutics, and methods of using such therapeutics, that are effective in treating, preventing, or ameliorating cancer cell proliferation.A · US 8,975,029 B2 · ¶ 6
In various aspects, the integrin alpha-2 binding agent is an antibody fragment.A · US 8,975,029 B2 · ¶ 8
The anti-periostin antibodies described herein decrease the collagen content of tumors, reduce infiltration of suppressive myeloid cell populations, such as granulocytic cells and tumor associated macrophages, while increasing macrophage polarization to an M1 phenotype, and increase the accumulation and anti-tumor properties of tumor infiltrating T cells.B · US 2022/0010003 A1 · ¶ 3
In some embodiments, the cancer comprises glioblastoma, pancreatic cancer, breast cancer, bladder cancer, kidney cancer, head and neck cancer, ovarian cancer, skin cancer, stomach cancer, mesothelioma, liver cancer, endometrial cancer, colon cancer, cervical cancer, prostate cancer, or lung cancer.B · US 2022/0010003 A1 · ¶ 4
patent.fyi, US 2026/0356962 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356962/, SHA-256 8c1b45b78052e05821cd5901b26f65d162abb8f2cb85b9821babc4019a719a4a